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Abstract
Background: Psychotropic medications are frequently used to treat challenging behaviour in children with intellectual
disabilities, despite a lack of evidence for their efficacy. This systematic review and meta-analysis aimed to determine
the safety and efficacy of pharmacological interventions for challenging behaviour among children with intellectual
disabilities.
Methods: Electronic databases were searched and supplemented with a hand search of reference lists and trial registries.
Randomised controlled trials of pharmacological interventions for challenging behaviour among children with intellectual
disabilities were included. Data were analysed using meta-analysis or described narratively if meta-analysis was
not possible. For quality assessment, the Cochrane Risk of Bias tool and the Grading of Recommendations
Assessment, Development and Evaluation (GRADE) approach were used.
Results: Fourteen studies including 912 participants met inclusion criteria. Antipsychotic medication reduced
challenging behaviour among children with intellectual disabilities in the short-term (SMD = −1.09, p < 0.001
for risperidone; SMD = −0.64, p <0.001 for aripiprazole). However, there were significant side-effects including
elevated prolactin levels (SMD= 3.22, p < 0.001) and weight gain (SMD = 0.82, p < 0.001). Evidence was inconclusive
regarding the effectiveness of anticonvulsants and antioxidants for reducing challenging behaviour. The quality of all
evidence was low and there were no long term follow up studies.
Conclusions: Antipsychotic medications appear to be effective for reducing challenging behaviour in the short-term
among children with intellectual disabilities, but they carry a risk of significant side effects. Findings from this review
must be interpreted with caution as studies were typically of low quality and most outcomes were based on a small
number of studies. Further long-term, high-quality research is needed to determine the effectiveness and safety of
psychotropic medication for reducing challenging behaviour.
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Background
Intellectual disability or intellectual developmental
disorder (IDD) is characterised by an impairment of men-
tal ability and adaptive functioning that originates in child-
hood [1]. One per cent of the population are thought to
have IDD [2]. Children, young people and adults with
IDD are vulnerable to developing mental ill health and
face health inequalities [3, 4]. A common problem in this
population is challenging behaviour, which presents as
episodic aggression towards others and the environment,
self-injury, and a host of other behaviours that may be
seen as socially unacceptable and prevent the individual
from fully participating in day to day life [5]. The preva-
lence of such problems is lower in the community than in
hospital or congregate settings but rates vary according to
features of study design, such as how challenging behav-
iour is measured [6]. Challenging behaviour is one of the
factors leading to the exclusion of individuals from their
local communities, precipitation of abusive practices and
poorer quality of life for the individual and the family
carers [7–9]. Staff caring for individuals with IDD and
challenging behaviour may report burnout and low job
satisfaction [10, 11].
A variety of psychosocial interventions have been used
in the treatment and management of challenging behav-
iour but often medication may be added, or may be used
as the sole treatment [12]. It is thought that psycho-
tropic medication, particularly antipsychotic drugs, are
prescribed all too often for these individuals and may be
administered long-term [13–15].The justification for
their use in the absence of an ICD or DSM psychiatric
disorder is commonly cited as an improvement in mood
dysregulation. However, such drugs have significant side
effects including the metabolic syndrome, movement
disorders, such as drug induced Parkinsonism and tard-
ive dyskinesia, and osteoporosis [16–19]. The impact of
psychotropic medication on challenging behaviour is less
well established [20].
A multinational study using the IMS Prescribing
Insights database investigated prescriptions for children
and adults with Autism Spectrum Disorders (ASD). The
authors found that prescriptions for children far outnum-
bered those for adults with the most commonly prescribed
medication being risperidone; although the class of drug
varied across countries [21, 22]. A further investigation of
the use of psychotropic medication for children and young
persons aged 0–24 years with ASD in primary care in the
UK indicated that approximately 12.6 % had a comorbid
intellectual disability and that psychostimulants and hyp-
notics were prescribed most often [23]. The findings fur-
ther showed that there was an increase in prescriptions
issued over a period of 16 years.
Given the risks and substantial prescribing of psycho-
tropic medications, for a population who are known to
face health inequalities and who are unable to identify
symptoms of disease or seek help early, it is paramount
that evidence is gathered to inform routine care and im-
prove standards [24].
Aims of the study
This review aims to summarise the available empirical
evidence regarding the efficacy and safety of pharmaco-
logical interventions for children with intellectual dis-
abilities and challenging behaviour.
There are currently no systematic reviews that com-
prehensively evaluate the broad range of pharmaco-
logical interventions that have been used with this
population. Therefore, it is hoped that the findings from
the review and meta-analysis will assist in guiding clini-
cians and researchers to optimise prescription patterns
for a vulnerable population group.
Methods
This review and meta-analysis followed methodological
and reporting guidelines from the National Institute for
Health and Care Excellence (NICE) [25], Cochrane
Handbook for Systematic Reviews of Interventions [26]
and Preferred Reporting Items for Systematic Reviews
and Meta-Analyses (PRISMA; http://www.prisma-state-
ment.org/). A completed PRISMA checklist is available
(see Additional file 1).
Ethical approval was not required as the study was a
systematic review. The full review protocol is available
from https://www.nice.org.uk/guidance/ng11.
Eligibility Criteria
Types of trials
Studies were included if they were randomised con-
trolled trials (RCTs) or cluster RCTs with at least 10
participants per arm.
Types of participants
Eligible participants were children and young people up
to the age of 18 years with intellectual disabilities and
challenging behaviour. Intellectual disabilities were de-
fined by the following criteria: an intelligence test score
of less than 70, significant impairment of social or adap-
tive functioning, and onset in childhood. This corre-
sponds to ’mental retardation’ as described in the major
taxonomies DSM-5 and ICD-10 [1, 27]. Studies involv-
ing children with autism but which did not explicitly re-
port co-occurring intellectual disability were included
unless it was clear that participants had high-functioning
autism. This decision was based on evidence suggesting
that 50–70 % of individuals with autism spectrum disor-
ders also have intellectual disabilities [28, 29]. Challen-
ging behaviour was defined as “culturally abnormal
behaviour(s) of such an intensity, frequency or duration
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that the physical safety of the person or others is likely to
be placed in serious jeopardy, or behaviour which is likely
to seriously limit use of, or result in the person being de-
nied access to, ordinary community facilities (p.4)” [5].
Types of interventions
Eligible interventions were pharmacological interven-
tions aimed at reducing or managing challenging behav-
iour, compared with treatment as usual, placebo or an
alternative active intervention.
Outcomes of interest
Critical outcomes
Critical efficacy outcomes were targeted challenging behav-
iour, adaptive functioning, quality of life, and service user
and carer satisfaction. Critical safety outcomes were adverse
events including sedation and somnolence, weight and pro-
lactin outcomes, seizures, and study discontinuation.
Secondary outcomes
Secondary outcomes were mental and psychological
health outcomes, effects on carer stress and resilience, ad-
verse effects on other people with intellectual disabilities,
rates of seclusion, rates of manual restraint, use of psycho-
active medication, premature death, rates of placement
breakdown and use of inpatient placements.
Search strategy
Electronic databases including Embase, Medline, PreMed-
line, PsycINFO, Cochrane Central Register of Controlled
Trials (CENTRAL), Cochrane Database of Systematic Re-
views (CDSR), Cochrane Database of Abstracts of Reviews
of Effects (DARE), Sociological Abstracts, Social Services
Abstracts, Education Resources Information Centre
(ERIC), British Education Index (BEI), International Bibli-
ography of the Social Sciences, (IBSS) and the Social Sci-
ences Citation Index (SSCI) were searched from their
inception until October 2014. We searched for unpub-
lished evidence using the NICE call for evidence process
[25], via a search of clinicaltrials.gov and through contact
with subject experts who were identified by members of
the guideline development group and prior literature
searches. Additional searches included a hand search of
study reference lists. The search for pharmacological evi-
dence formed part of a broader search for clinical trials on
intellectual disabilities and challenging behaviour. Full de-
tails of the search strategy for Medline can be found in
Additional file 2. This search string was translated for use
in all other databases listed.
Studies were screened for eligibility by two authors
(CM and BH) and on occasions where consensus could
not be reached a third author (SP) was consulted to de-
termine inclusion. Studies investigating drugs that were
no longer licensed, or involving drugs for which there
was no sound theoretical basis for their use in the treat-
ment of challenging behaviour, such as the cough sup-
pressant Dextromethorphan, were excluded based on
consultation with a chief pharmacist. Studies were ex-
cluded if participants had co-existing conditions, includ-
ing major mental disorders such as schizophrenia. In
cases where some, but not all, of a study’s participants
were eligible for the review - such as a mixed population
of individuals with and without intellectual disability -
study authors were asked to provide disaggregated data
for the subset of participants who met inclusion criteria.
Non-English language publications were excluded unless
an English version could be located. Conference ab-
stracts and dissertations were excluded.
Findings from studies exploring sleep problems, drug
discontinuation and those investigating biomedical inter-
ventions, such as dietary supplements, form part of a
separate review and are available in the full NICE guide-
line for challenging behaviour and learning disabilities
[30].
Data management
Outcome data were extracted into an electronic database
by one author (CM) and assessed for accuracy by a sec-
ond author (BH). The database captured information
about participant demographics, intervention character-
istics, study methodology, funding sources, and missing
data. Authors were contacted for further information if
data or study characteristics were not available.
Statistical analysis
Data were analysed with random effects meta-analysis
using the Review Manager software (RevMan, Cochrane,
Copenhagen) [31]. The standardised mean difference
(SMD; Hedges’ g) was used as the effect size for continu-
ous outcomes and studies were weighted using the in-
verse of variance. The SMD is a summary statistic that
allows outcomes from studies to be combined in meta-
analysis, regardless of the original scale of measurement.
This is useful in circumstances, such as the present re-
view, where studies use different psychometric tests (for
example, the Aberrant Behavior Checklist and the
Nisonger Child Behavior Rating Form) to assess the out-
come of interest. SMD is calculated as the difference in
mean outcome between groups, divided by the standard
deviation of the outcome among participants. SMDs of
0.20 were considered small, 0.50 medium and 0.80 or
more large following Cohen’s criteria [32]. For dichot-
omous outcomes, the risk ratio (RR) was used as the
measure of effect and studies were analysed with the
Mantel-Haenszel method [33]. The risk ratio indicates
the multiplication of the risk of an outcome in one
group compared to another. As estimates of effect size
can be misleading when event rates are low, outcomes
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with higher baseline risk (for example non-improvement
rather than improvement of challenging behaviour and
non-occurrence rather than occurrence of adverse
events) were selected for analyses [34].
Statistical heterogeneity was assessed with the I2 and
chi-squared (χ2) statistics and by visual inspection of for-
est plots. A p value of less than 0.10 or an I2 value of
40 % or higher was taken to indicate significant statis-
tical heterogeneity. In the event of significant heterogen-
eity, the protocol pre-specified study characteristics for
further investigation including the degree of learning
disability in the sample and the form of challenging be-
haviour. The findings of subgroup investigations will
only be presented if we were able to determine a plaus-
ible reason for heterogeneity. Otherwise, heterogeneity
was considered unexplained. The use of random-effects
models for meta-analysis reflects the assumption of un-
explained heterogeneity in findings.
Intent-to-treat was the preferred method of analysis.
In cases where studies reported data only for partici-
pants who completed the intervention (i.e. a completer
analysis), sensitivity analyses were conducted using
intent-to-treat principles, including all participants ran-
domized into the study and using non-improvement as a
worst case outcome scenario. Results of sensitivity ana-
lyses will only be reported if the effect size differs signifi-
cantly from the original effect estimate.
Risk of bias and quality assessment
We used The Cochrane Collaboration Risk of Bias Tool
[26] to assess the quality of each study. Risk of bias was
rated as low, high or unclear for each of the following
domains: sequence generation; allocation concealment;
blinding of participants, assessors, and providers; select-
ive outcome reporting; and incomplete data. Risk of bias
was assessed independently by two authors (CM and
BH) and disagreements resolved following discussion
with a third author (SP). Authors were contacted to re-
quest any missing information pertaining to risk of bias
assessments.
The Grading of Recommendations Assessment, Devel-
opment and Evaluation (GRADE) approach was used to
assess the quality of evidence for each outcome [35].
Briefly, the GRADE approach considers factors including
risk of bias; inconsistency; indirectness; imprecision; and
publication bias, when judging the quality of evidence.
When evidence is deemed to be high quality, the impli-
cation is that further research is very unlikely to change
the confidence in the estimate of effect. A judgement of
moderate quality suggests that further research is likely
to have an important impact on the confidence in the
estimate of effect and may change the estimate. Low
quality evidence suggests that further research is very
likely to have an important impact on the confidence in
the estimate of effect and is likely to change the esti-
mate, and a judgement of very low quality evidence indi-
cates that the effect estimate is very uncertain.
Results
Results of the search
The search process identified 14,151 records for screen-
ing. From this, 14 primary studies were eligible for re-
view. Figure 1 depicts a flow diagram of the selection
process.
Study characteristics
Eligible studies ranged in date from 2001–2013 and in-
cluded a total of 912 participants. All but one study pro-
vided sufficient data for meta-analysis. The results of this
study will be presented narratively [36]. Of the studies in-
cluded in the review, nine were from the USA [37–45],
three were from Iran [36, 46, 47], one was from Canada
[48] and one was conducted across multiple countries
[49]. Antipsychotics were the most common class of drug
and were evaluated in nine studies [37, 41–46, 48, 49]. An-
ticonvulsants were evaluated in three studies [39, 40, 47],
antioxidants in one study [38] and gamma-aminobutyric
acid (GABA) analogues in one study [36]. Duration of
treatment ranged from six to twelve weeks. The mean age
of participants was 9 years (range 7 – 11 years) and 21 %
of the sample were female. Twelve studies included partic-
ipants with an autistic spectrum disorder [36, 38–48] and
co-existing intellectual disability was explicitly reported in
four of these studies [39, 42, 45, 48]. Two studies included
children with mild to moderate intellectual disabilities
[37, 49]. Twelve studies compared pharmacological
treatment to placebo [36–41, 43–45, 47–49] and two
conducted head-to-head trials comparing anti-
psychotic medication [42, 46]. All studies measured
outcomes immediately following the end of treatment
and none reported long-term follow-up data. No data
were available for any secondary outcomes. There
were no studies that met inclusion criteria with re-
spect to pharmacological interventions for self-
injurious behaviour in children.
Further characteristics of included studies are shown
in Table 1.
Risk of bias for included studies
Figure 2 provides an overview of the risk of bias assessment
for included studies.
Randomisation procedures were adequate in six stud-
ies and unclear in eight studies. There was a low risk of
bias for allocation concealment in six of the studies and
concealment was unclear for the eight remaining studies.
The majority of studies carried out adequate procedures
to ensure that participants and study personnel were
blind to treatment status. However, for two studies
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blinding was unclear and risk of bias was high for the
remaining two studies, as one had an open label design
and the other did not blind study personnel. In terms of
blinding of outcome assessment, eight studies were
deemed to be low risk of bias, five were unclear and one
open label trial was considered to be at a high risk of
bias. There was a low risk of bias for selective outcome
reporting in 11 studies, an unclear risk for two studies
and a high risk in one study. Twelve of the 14 studies
were deemed to be at a high risk of bias for other rea-
sons; most commonly because of affiliations with
pharmaceutical companies, the exclusion of participants
who had previously been unresponsive to medication
and between group differences in concomitant medication.
Based on the GRADE approach, the quality of evi-
dence ranged from low to very low for all outcomes.
This was mainly due to small sample sizes and risk of
bias within studies. Full GRADE profiles for included
evidence can be found in Additional file 3.
Efficacy and safety outcomes by drug class
Antipsychotics
Antipsychotics were evaluated in nine studies [37, 41–46,
48, 49].The types of drugs investigated were risperidone,
aripiprazole, haloperidol and olanzapine.
Effectiveness outcomes
Challenging behaviour Five studies with 325 partici-
pants compared risperidone to placebo [37, 41, 45, 48, 49].
Challenging behaviour was assessed using The Nisonger
Child Behavior Rating Form (NCBRF) Conduct Problems
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Fig. 1 PRISMA flow chart depicting selection of studies
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subscale [50] in three studies [37, 48, 49] and the Aberrant
Behavior Checklist Irritability Subscale (ABC-I) [51] and
Clinical Global Impressions-Improvement (CGI-I) [52] in
two studies [41, 45].
Three of these studies included children with autism
who did not have intellectual disability [37, 48, 49].For
these studies, we obtained disaggregated data sets from
authors which included data only from children with in-
tellectual disabilities and used these for analyses.
Risperidone reduced challenging behaviour in compari-
son to placebo based on endpoint (SMD= −1.09, 95 %
confidence interval [CI] -1.39 to −0.79, z = 7.07, p < 0.001)
and change from baseline scores (SMD= −0.98, CI −1.49
to −0.47, p < 0.001). Results are depicted in Fig. 3. Dichot-
omous measures of improvement, defined as a 25 % im-
provement in ABC-I scores and a CGI-I rating of much
improved or very much improved provided further sup-
port for the effectiveness of risperidone in reducing chal-
lenging behaviour, relative to placebo (RR = 0.42, CI 0.28
to 0.64, p < 0.001).
Two studies with 316 participants compared the ef-
fectiveness of aripiprazole to placebo in the treatment of
challenging behaviour [43, 44]. Aripiprazole was found
to be superior to placebo in terms of reducing the sever-
ity of challenging behaviour based on ABC-I scores
(SMD = −0.64, CI −0.91 to −0.36, p < 0.001) and dichot-
omous improvement outcomes, classed as a 25 % im-
provement in ABC-I scores and a CGI-I rating of much
improved or very much improved (RR = 0.65, CI 0.50 to
0.84, p = 0.001) (see Fig. 3).
One head-to head study compared the effectiveness of
aripiprazole to risperidone [46] and found that children
who received risperidone showed lower levels of challen-
ging behaviour based on the ABC-I than those given ari-
piprazole, however the precision of this estimate was
poor and statistical estimates of effect were inconclusive
(SMD = 0.38, CI −0.14 to 0.90, p = 0.15).
A small open label study [42], involving 12 participants
indicated that children who received olanzapine showed
lower levels of challenging behaviour at the end of treat-
ment than those who received haloperidol (SMD= −1.40,
CI −2.73 to −0.08, p = 0.04).
Adaptive functioning Three studies [37, 48, 49] pro-
vided information on the effect of risperidone on partici-
pants’ adaptive social functioning. Analysis demonstrated
Table 1 Characteristics of included studies
Study Diagnosis Targeted CBa(measure) Intervention (dose mg/day) Comparison (dose
mg/day)
Treatment
duration
Akhondzadeh
2008
ASD Severely disruptive symptoms
(ABC total)
Piracetam (800) +
risperidone (3)
Placebo + risperidone
(3)
10 weeks
Aman 2002 Mild to moderate ID Conduct problems (NCBRF
conduct)
Risperidone (1.2) Placebo 6 weeks
Ghanizadeh
2013
ASD Irritability (ABC-I) Aripiprazole (5.5) Risperidone (1.1) 8 weeks
Hardan 2012 ASD Irritability (ABC-I) N-acetylcysteine (2700) Placebo 12 weeks
Hellings 2005 ASD + IDb Irritability (ABC-I) Valproate (20)c Placebo 8 weeks
Hollander 2010 ASDd Irritability (ABC-I) Valproate (375) Placebo 8 weeks
Kent 2013e ASD Irritability (ABC-I) Risperidone (1.8)f Placebo 6 weeks
Malone 2001 ASD +mild to severe
IDg
Hyperactivity (CPRS-H) Olanzapine (10)f Haloperidol (2.5) 6 weeks
Marcus 2009 ASD Irritability (ABC-I) Aripiprazole (10)h Placebo 8 weeks
Owen 2009 ASD Irritability (ABC-I) Aripiprazole (8.9) Placebo 8 weeks
Rezaei 2010 ASD Irritability (ABC-I) Topiramate (200) +
risperidone (2)f
Placebo + risperidone
(2)f
8 weeks
RUPP 2002i ASD +mild to severe
ID
Irritability (ABC-I) Risperidone (1.8) Placebo 8 weeks
Shea 2004 ASD +mild to
moderate ID
Conduct problems (NCBRF
conduct)
Risperidone (1.5) Placebo 8 weeks
Snyder 2002 Mild to moderate IDj Conduct problems (NCBRF
conduct)
Risperidone (1) Placebo 6 weeks
Notes: ASD = autism spectrum disorder; CB = challenging behaviour; ID = intellectual disability; N = number randomised; ABC total = Aberrant Behaviour Checklist total
score; ABC-I = Aberrant Behaviour Checklist: Irritability; CGI-I = Clinical Global Impressions: Improvement; CPRS-H Children’s Psychiatric Rating Scale: Hyperactivity; NCBRF =
Nisonger Child Behaviour Rating Form: Conduct problems. a Primary outcome measure for meta-analysis; b 13 % of sample had borderline to average intelligence; 87 %
were diagnosed with ID; c 20 mg/kg/day; d15% of sample had Asperger’s syndrome; e Three armed trial: high dose risperidone and placebo arms used in meta-analysis; f
Maximum dose; g 8 % of participants had normal cognitive functioning, all others had mild to severe ID; h Data from high, moderate and low dose conditions combined in
meta-analyses; i Research Units on Pediatric psychopharmacology (RUPP) Autism Spectrum Disorder Network; j 2 % of participants had borderline intellectual functioning;
all others had mild to moderate ID.
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a large effect size (SMD= 0.86, CI 0.42 to 1.30, p = <0.001)
suggesting that risperidone improved children’s adaptive
social functioning when compared to placebo. However,
there was evidence of statistical heterogeneity (χ 2 = 3.34,
p = 0.19, I2 = 40 %), which were not readily explained by
differences in study characteristics, and therefore results
should be interpreted with caution.
Quality of life Children who received aripiprazole showed
higher quality of life scores at the end of treatment than
those given placebo [43, 44]. However, confidence intervals
crossed the line of no effect and, thus, the estimate of effect
was inconclusive (SMD= 0.60, CI −0.17 to 1.37, p = 0.13).
Furthermore, there was significant unexplained statistical
heterogeneity for this effect (χ2 = 6.34, p = 0.01, I2 = 84 %)
suggesting caution in interpretation.
Service user and carer satisfaction There were no data
available for the effect of any antipsychotic medication
on service user and carer satisfaction.
Safety outcomes
Weight Risperidone was associated with greater weight
gain than placebo [37, 41, 45, 48, 49](SMD= 0.82, CI 0.57
to 1.06, p < 0.001; RR 0.91, CI 0.85 to 0.96, p = 0.002; see
Fig. 4).
Aripiprazole was associated with greater levels of weight
gain [43] (SMD= 0.48, CI 0.17 to 0.80, p = 0.003; see Fig. 4)
and increased the risk of clinically significant weight gain
when compared with placebo at the end of intervention
[43, 44] (RR = 0.79, CI 0.71 to 0.88, p < 0.001).
Olanzapine was found to increase weight gain to a
greater extent than haloperidol [42], although the preci-
Fig. 2 Risk of bias summary for included studies
Fig. 3 The effect of risperidone and aripiprazole on challenging behaviour in children with intellectual disabilities
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sion of this estimate was poor, possibly as a result of small
sample size (SMD= 1.26, CI −0.03 to 2.54, p = 0.06).
Sedation There were greater levels of sedation among
children treated with risperidone [37, 41, 45, 48, 49]
and aripiprazole [43, 44] than those who received pla-
cebo (RR = 0.53, CI 0.42 to 0.68, p < 0.001 for risperi-
done; RR = 0.83, CI 0.76 to 0.91, p < 0.001 for
aripiprazole; see Fig. 5). However, there was signifi-
cant unexplained heterogeneity for the effect with ris-
peridone (χ2 = 10.80, p = 0.03, I2 = 63 %).
One head-to-head study comparing risperidone to ari-
piprazole [46] found no difference in levels of sedation
between groups (RR = 0.95, CI 0.74 to 1.22, p = 0.69).
A study comparing olanzapine to haloperidol [42] sug-
gested that olanzapine increased drowsiness to a greater
extent than haloperidol, but statistical estimates of this
effect were inconclusive due to wide confidence intervals
(RR = 0.25, CI 0.04 to 1.63, p = 0.15).
Prolactin Risperidone was found to significantly increase
prolactin. Studies showed that prolactin levels were over
three times higher among children given risperidone than
those given placebo [37, 45, 49] (SMD= 3.22, CI 1.68 to
4.75, p < 0.001; see Fig. 4). All studies demonstrated higher
levels of prolactin among children treated with risperi-
done, compared to placebo, however this effect showed
significant heterogeneity (χ2 = 30.66, p < 0.001, I2 = 93 %),
likely due differences in the magnitude of effect across
studies. More children had elevated prolactin levels with
risperidone than placebo [37, 49] (RR 0.91, CI 0.85 to
0.97, p < 0.001). One child was found to have experienced
oligomenorrhea - a prolactin-related adverse event – fol-
lowing treatment with risperidone [41], but analysis was
Fig. 4 The effect of aripiprazole and risperidone on weight and prolactin levels in children with intellectual disabilities and challenging behaviour
Fig. 5 The effect of aripiprazole and risperidone on sedation in children with intellectual disabilities and challenging behaviour
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inconclusive as to the relative risk of this event between
groups (RR 0.97, CI 0.89 to 1.05, p = 0.44).
Evidence from two studies was inconclusive as to
whether aripiprazole increased prolactin levels to a
greater extent than placebo [43, 44] (RR 1.05, CI 0.99 to
1.10, p = 0.08).
Seizures Evidence was inconclusive as to whether treat-
ment with risperidone [45] or aripiprazole [43] increased
the risk of seizures when compared to placebo (RR = 1.02,
CI 0.97 to 1.08, p = 0.50 for risperidone; RR = 1.03, CI 0.98
to 1.08, p = 0.28 for aripiprazole).
A head-to-head study comparing risperidone to aripi-
prazole [46] found no difference in the rate of seizures
between groups (RR = 1.03, CI 0.94 to 1.13, p = 0.49).
Study discontinuation There were no significant dif-
ferences in the rate of study discontinuation due to ad-
verse events in placebo-controlled studies of risperidone
[37, 41, 45, 48] or aripiprazole [43, 44] (RR = 0.99, CI 0.96
to 1.03, p = 0.76 for risperidone; RR = 0.96, CI 0.89 to 1.04,
p = 0.33 for aripiprazole), or within a head-to-head study
of risperidone compared to aripiprazole [46] (RR = 1.03,
CI 0.94 to 1.13, p = 0.49).
Anticonvulsants
The efficacy of anticonvulsants for the treatment of chal-
lenging behaviour was explored in three studies, which
included treatment with valproate and topiramate [39,
40, 47].
Efficacy outcomes
Challenging behaviour Two studies involving 57 chil-
dren with autism investigated the effectiveness of valpro-
ate when compared with placebo and found mixed
results [39, 40]. Evidence was inconclusive as to the ef-
fectiveness of valproate in reducing the severity of chal-
lenging behaviour based on ABC-I scores (SMD = −0.06,
CI −0.75 to 0.63, p = 0.86) and there was significant un-
explained heterogeneity in findings (χ2 = 1.71, p = 0.19,
I2 = 41 %). However, a dichotomous measure of improve-
ment incorporating CGI, ABC-I and Modified Overt Ag-
gression Scale [53] scores, based on one of the studies
[40] suggested that more children showed an improve-
ment in challenging behaviour following treatment with
valproate than those given placebo (RR = 0.41, CI 0.21 to
0.80, p = 0.009). Findings are presented in Fig. 6.
One study with 40 participants compared the effective-
ness of treatment with topiramate combined with risper-
idone to a control condition in which participants
received placebo with risperidone [47]. Risperidone was
reportedly added to the intervention and control condi-
tions in order for the study to obtain ethical approval.
Combined treatment with topiramate and risperidone
improved challenging behaviour to a greater extent than
treatment with placebo plus risperidone (SMD = −1.88,
CI −2.63 to −1.12, p < 0.001; see Fig. 6).
Other critical efficacy outcomes No data were available
for the effect of anticonvulsants on adaptive functioning,
quality of life or service user and carer satisfaction.
Safety outcomes
There were no data for the effect of anticonvulsants on
prolactin outcomes or seizures.
Weight Studies of valproate [39, 40] and of combined
treatment with topiramate and risperidone [47] were in-
conclusive as to whether anticonvulsants increase weight
gain, relative to placebo (SMD = 0.29, CI −0.24 to 0.82,
p = 0.28 for weight change with valproate; SMD = −0.24,
CI −0.87 to 0.38, p = 0.44 for weight at endpoint for
topiramate and risperidone; see Fig. 7).
Sedation and somnolence One placebo-controlled
study of combined treatment with topiramate added to
risperidone [47] and two exploring valproate [39, 40]
were inconclusive as to the effect of these anticonvul-
sants on sedation (RR = 1.19, CI 0.93 to 1.51, p = 0.16 for
topiramate with risperidone; RR = 1.19, CI 0.90 to 1.56,
p = 0.23 for valproate; see Fig. 8).
Study discontinuation Analysis of two studies was in-
conclusive as to whether treatment with valproate in-
creased study discontinuation due to adverse events to a
greater extent than placebo [39, 40] (RR = 0.95, CI 0.83
to 1.08, p = 0.41).
Antioxidants
Efficacy outcomes
Challenging behaviour
N-acetylcysteine was compared with placebo for the
treatment of challenging behaviour in a pilot study in-
cluding 33 children with autism [38]. Children who re-
ceived N-acetylcysteine showed lower levels of
challenging behaviour than those given placebo, al-
though confidence intervals crossed the line of no effect,
suggesting that results were inconclusive (SMD = −0.70,
CI −1.46 to 0.05, p = 0.07; see Fig. 9).
Other critical efficacy outcomes
No data were available for the effect of antioxidants on
adaptive functioning, quality of life or service user and
carer satisfaction.
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Safety outcomes
There were no data for the effect of antioxidants on
weight, sedation, prolactin outcomes or seizures.
Study discontinuation
One small study was inconclusive as to the effect of N-
acetylcysteine on study discontinuation due to adverse
events [38] (RR = 0.93, CI 0.78 to 1.11, p = 0.42).
Gamma-aminobutyric acid (GABA) analogues
Efficacy outcomes
Challenging behaviour
One study involving 40 children with autism compared
combined treatment with piracetam and risperidone to a
control condition which included treatment with placebo
plus risperidone [36]. It was not possible to include this
study in meta-analysis, as data were not presented as means
and standard deviations. However, the paper reports that
challenging behaviour was significantly improved following
treatment with piracetam plus risperidone when compared
with the control condition (F = 5.85, d.f. = 1, p = 0.02).
Other critical efficacy outcomes
No data were available for the effect of GABA analogues
on adaptive functioning, quality of life or service user
and carer satisfaction.
Safety outcomes
There were no data for the effect of GABA analogues on
weight, prolactin, seizures or study discontinuation.
Sedation
Based on one study, analysis was inconclusive as to the ef-
fect of piracetam on daytime drowsiness [36] (RR = 1.18, CI
0.71 to 1.97, p = 0.52).
Discussion
Main findings
This systematic review suggests that antipsychotic medi-
cations may be effective in reducing challenging behav-
iour among children with intellectual disabilities in the
short-term. Aripiprazole and risperidone reduced post-
treatment challenging behaviour with effect sizes in the
moderate to large range. However, there was a lack of
evidence regarding the long-term effectiveness of anti-
psychotic medication for reducing challenging behaviour
and the quality of evidence was low. Evidence for the ef-
fectiveness of anticonvulsants and antioxidants was in-
conclusive. GABA analogues were reportedly effective
for the treatment of challenging behaviour in one small
study.
This review also demonstrates that antipsychotic
medication was associated with a range of side effects
among children including significant weight gain,
Fig. 6 The effect of valproate and topiramate (added to risperidone) on challenging behaviour in children with intellectual disabilities
Fig. 7 The effect of valproate and topiramate (added to risperidone) on weight in children with intellectual disabilities and challenging behaviour
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increased prolactin levels and sedation. Such side effects
were apparent after six to twelve weeks of treatment.
Available evidence did not permit exploration of the
long term consequences of these side effects, or of any
other effects that may emerge with prolonged treatment.
However, existing evidence confirms that a variety of
side effects have been noted following the use of anti-
psychotic medication including somnolence, extrapyr-
amidal symptoms, increased prolactin concentrations,
significant weight gain and cardiovascular dysfunction
[37, 43, 49, 54]. Elevated prolactin levels may be of par-
ticular concern for children, as hyperprolactinemia can
adversely affect long-term physical and sexual develop-
ment, having been associated with conditions such as
amenorrhea, erectile dysfunction and osteoporosis [55, 56].
Despite evidence of significant side effects, antipsychotic
medications are still commonly prescribed for the treat-
ment of behavioural disturbance among children and ado-
lescents with intellectual disability [57].
Notably, many of the drugs investigated in this re-
view have been used outside of their licenced indica-
tion. This accords with evidence that suggests that
off-label prescribing may be as high as 46 % among
individuals with intellectual disabilities [13]. Only ari-
piprazole and risperidone have been approved by the
U.S Food and Drug Administration for irritability as-
sociated with autistic disorder in paediatric patients
[58, 59]. A recent audit suggested that nearly three
quarters of individuals with intellectual disabilities
were prescribed antipsychotic medication and a third
of these were prescribed to treat challenging behav-
iour [12].
Given the possibility that individuals with intellectual
disabilities may be more susceptible to drug side-effects,
and the lack of firm evidence for the effectiveness of anti-
convulsants, GABA analogues and antioxidants, clinicians
must be cautious when choosing to prescribe drugs off-
label for the treatment of challenging behaviour [60, 61].
Strengths and limitations of the review
The strengths of this review and meta-analysis include a
rigorous methodology, and investigation of a wide range
of pharmacological interventions among children with
intellectual disabilities. A review of this type and scale
has not previously been conducted in this area. Further-
more, the review incorporated previously unpublished
data, further adding to the utility of this analysis.
Nevertheless, the results of this review must be inter-
preted with caution as most outcomes were based on a
small number of studies, the quality of evidence ranged
from low to very low and information was only available
for short-term outcomes. Study quality was compromised
most commonly by small sample sizes, but also by inad-
equate reporting of methods of blinding, randomisation
and allocation concealment by study authors. Therefore,
conclusions drawn from this review are susceptible to
Fig. 8 The effect of valproate and topiramate (added to risperidone) on sedation in children with intellectual disabilities and challenging behaviour
Fig. 9 The effect of N-acetylcysteine on challenging behaviour in children with intellectual disabilities
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change as further evidence becomes available. Secondly,
the majority of participants in the review were diagnosed
with autism. While autism is frequently associated with a
concurrent diagnosis of intellectual disabilities, and the re-
view included disaggregated data sets of individuals with
intelligence test score of less than 70, where available, it
remains possible that some participants did not meet cri-
teria for intellectual disability. It is not clear how this
would affect the interpretation of findings.
Conclusions
Available evidence suggests that antipsychotic medica-
tions may be effective for reducing challenging behav-
iour in the short-term among children with intellectual
disabilities. Findings from this review must be inter-
preted with caution as studies were generally of low
quality and most outcomes were based on a small num-
ber of studies. Further multicentre research utilising ran-
domised designs and health related quality of life is
needed to determine the clinical and cost effectiveness
of psychotropic medication for challenging behaviour ei-
ther alone or in addition to psychosocial interventions.
Longitudinal follow up of participants can also shed fur-
ther light on issues of safety especially as such treat-
ments may be taken over extended periods of time.
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